NCT03164057 A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03151408 An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Status TERMINATED Phase PHASE3
NCT03151304 A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes Status TERMINATED Phase PHASE2
NCT03146871 Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Status TERMINATED Phase PHASE2
NCT03113643 SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Status RECRUITING Phase PHASE1
NCT03094637 Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome Status UNKNOWN Phase PHASE2
NCT03092674 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Status COMPLETED Phase PHASE2/PHASE3
NCT03072043 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Status COMPLETED Phase PHASE1/PHASE2
NCT03066648 Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Status COMPLETED Phase PHASE1
NCT03047993 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Status COMPLETED Phase PHASE1/PHASE2
NCT02995655 CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Status COMPLETED Phase PHASE1
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Status COMPLETED Phase PHASE3
NCT02985190 A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders Status COMPLETED Phase PHASE2
NCT02966782 A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) Status COMPLETED Phase PHASE1
NCT02959437 Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Status TERMINATED Phase PHASE1/PHASE2
NCT02954653 A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia Status TERMINATED Phase PHASE1
NCT02953561 Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Status TERMINATED Phase PHASE1/PHASE2
NCT02942290 A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02929498 Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) Status TERMINATED Phase PHASE1/PHASE2
NCT02835794 A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) Status WITHDRAWN Phase PHASE1/PHASE2